INTRODUCTION
It has been suggested -that active oxygen species derived from molecular oxygen contribute to tissue injury. Endothelial cells have been proposed as the initial site of tissue injury by the active oxygen species in the vascular system, because they are ubiquitous and located at the blood/tissue barrier [1] . Moreover, extracellular fluids outside of endothelial cells contain only small quantities of endogenous enzymes, such as superoxide dismutase, catalase and glutathione peroxidase [2, 3] , protective against the active oxygen species. It appears that vascular endothelial cells intrinsically generate active oxygen species when subjected to anoxia and reoxygenation, conditions observed in ischaemic and reperfused tissues [4] .
Endothelial cells are a rich source of the superoxidegenerating enzyme xanthine oxidase (XOD) [1] . XOD has been demonstrated to be the source of most of the observed active oxygen species, because of the marked inhibition of radical generation by the potent XOD inhibitors allopurinol and oxypurinol [4, 5] . XOD catalyses the two-step oxidation of purine, such as hypoxanthine, through xanthine, to urate. In vivo, the enzyme may exist in either of two forms, each of which catalyses the above reaction: the dehydrogenase form, which uses NAD+ as an electron acceptor and therefore does not generate superoxide, and an oxidase form, which uses molecular oxygen as an electron acceptor and thereby produces the superoxide. The dehydrogenase form, which predominates in most tissues under normal conditions, can be converted into the oxidase form by irreversible limited proteolysis and/or reversible oxidation of thiol groups in ischaemia [6, 7] .
In a number of tissues, including mammary gland, liver, heart, nature, and both lysine and arginine residues are involved in the binding. lung and intestine, XOD has been found in endothelial cells of capillaries by immunohistochemical research [1, 8] . Recently, it has been demonstrated that XOD is not only a cytoplasmic enzyme, but that it is also localized on the outside surface of the endothelial-cell plasma membrane [9] . However, it is still not known how XOD localizes on the cell surface.
In the present study the binding of XOD to heparin-Sepharose and to cultured endothelial-cell surfaces via heparan sulphate proteoglycans are explored. The effect of heparin injection on the plasma XOD level in man has also been studied.
EXPERIMENTAL Materials
Xanthine, horseradish peroxidase (HRP, type IV), protamine and heparinase were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). Phenylmethanesulphonyl fluoride (PMSF), aprotinin, Nitroblue Tetrazolium (NBT) and trinitrobenzenesulphonic acid (TNBS) were purchased from Wako Pure Chemical Industries (Osaka, Japan). Phenylglyoxal was purchased from Aldrich Chemical Company (Milwaukee, WI, U.S.A.). Heparin was obtained from Kodama Co. (Tokyo, Japan). DEAE-cellulose, hydroxyapatite and heparitinase were purchased from Seikagaku Co. (Tokyo, Japan). DEAESepharose, Sephacryl S-300 and heparin-Sepharose CL-6B were products of Pharmacia LKB Biotechnology (Uppsala, Sweden). 96-Well immunoplates were purchased from Nunc (Roskilde, Denmark). Dulbecco's modified Eagle medium (DMEM) was purchased from Nissui Pharmaceutical Co. (Tokyo, Japan). Porcine aortic endothelial (PAE) cells were kindly given by T'akeda Chemical Industries (Osaka, Japan).
Abbreviations used: h-XOD, human xanthine oxidase; HRP, horseradish peroxidase; PAE cell, porcine aortic endothelial cell; PMSF, phenylmethanesulphonyl fluoride; NBT, Nitroblue Tetrazolium; TNBS, trinitrobenzenesulphonic acid; DMEM, Dulbecco's modified Eagle medium; EDRF, endothelium-derived relaxing factor; EC-SOD, extracellular-superoxide dismutase.
* To whom correspondence should be addressed.
Purification of human milk xanthine oxidase (h-XOD)
h-XOD was purified from collected human milk by the method described by Zeise and Zikakis [10] , but with several modifications.
Sodium salicylate and Na2EDTA were added into the thawed milk to final concentrations of 2 mM (salicylate) and 0.01 % (Na2EDTA). A 600 ml portion of the mixture was added to an equal volume of 0.2 M K2HP04 containing 8 mM sodium salicylate, 2 mM cysteine, 0.5 mM PMSF and 100000 units of aprotinin, and the resultant mixture was then incubated at 40°C for 2 h with frequent stirring. After the sample was cooled to 4°C, Triton X-100 was added to a final concentration of After stirring overnight, the solution was centrifuged at 10000 g for 30 min. The precipitate was dissolved with a minimal volume of distilled water and dialysed against 5 mM sodium pyrophosphate buffer, pH 8.5 containing 2 mM sodium salicylate and 0.005 % Na2EDTA (Buffer A). The dialysed enzyme was passed through a column (3 cm x 25 cm) of DEAE-cellulose equilibrated with Buffer A. The active fractions were pooled and concentrated with YM-10 membrane filter, followed by application to a column (4.5 cm x 10 cm) of DEAE-Sepharose equilibrated with Buffer A. The column was eluted with a linear gradient of sodium pyrophosphate buffer, pH 8.5, between 5 mM and 0.1 M, containing sodium salicylate and Na2EDTA at the same concentrations as in Buffer A. The active fractions were pooled, concentrated with a YM-10 membrane filter and dialysed against Buffer A. The enzyme was then applied to a column (1.2 cm x 10 cm) of hydroxyapatite equilibrated with Buffer A. XOD was eluted stepwise from the column by successive washing with Buffer A containing 0.1, 0.2, 0.3, 0.4 and 1 M NaCl. XOD was eluted mainly in the 0.3 and 0.4 M NaCl steps. The concentrated XOD preparation was applied to a Sephacryl S-300 column (2 cm x 90 cm) equilibrated with Buffer A, and active fractions were pooled and concentrated with a YM-10 membrane filter.
The A280/A450 ratio of the purified enzyme was about 5.2. The purity of h-XOD was checked by SDS/PAGE (7.5 % polyacrylamide gel) under reducing conditions. A single protein band with a molecular mass of 145 kDa was observed upon staining of the gel with Coomassie Brilliant Blue R250. The A280/A450 ratio and monomeric molecular mass are almost identical with those reported for XODs from other sources [11, 12] .
Assay of h-XOD activity
Enzyme solution ,ll) was added to 1 ml of 50 mM sodium carbonate buffer, pH 10.2, containing 0.12 mM xanthine, 0.12 mM Na2EDTA, 60 ,tg/ml BSA and 0.03 mM NBT, and then incubated at 37 'C for 30 min. The enzyme reaction was stopped by the addition of 50 ,ul of 6 mM CuCl2 solution, and the absorbance at 560 nm was measured.
E.l.i.s.a. for h-XOD
The antisera to h-XOD were raised in Japanese White rabbits by subcutaneous injection of the purified h-XOD (200 ,ug/rabbit) in peated four times every 2 weeks, and the rabbits were bled 1 week after the final injection. The antibody was purified by (NH4)2504 precipitation (33 % satn.) followed by the DEAE-cellulose column chromatography.
The HRP-labelled antibody was prepared with glutaraldehyde as a cross-linking reagent by the method as described previously [13] .
An 80 ,1 portion of 50 ,ug/ml antibody dissolved in 50 mM sodium carbonate buffer, pH 9.5, containing 0.02 % NaN3 was added into each well of Immunoplates and left overnight at 4 
Heparin-Sepharose column chromatography
The samples were dialysed against 25 mM sodium phosphate buffer, pH 7.5, or mixed with excessive volume of 25 mM buffer at various pH values (sodium acetate buffer, pH 5.5, sodium phosphate buffer, pH 6.5 and 7.5, Tris/HCl buffer, pH 8.5 and 9.5) before application.
The samples were applied to a heparin-Sepharose column equilibrated with the indicated buffer and washed with the same buffer. The bound h-XOD was then eluted with stepwise additions of buffer containing increasing concentrations of NaCl (0.1 M increments) or a linear gradient of NaCl (0 -. 1 M) in the buffer.
Binding of h-XOD to PAE cells
The cells were cultured and maintained in DMEM supplemented with 100% fetal-calf serum. They were kept in a 5 %-CO2 atmosphere at 37 'C.
The experiments were performed using confluent endothelial cell monolayers in 35 mm-diameter tissue-culture dishes as follows. The monolayers were rinsed three times with 1 ml of DMEM containing 10 mM Hepes and 0.50% BSA (DMEM-BSA), 1 ml ofDMEM/BSA with or without 1 unit ofheparitinase and/or 2 units of heparinase were then added and the cells were incubated for another 2 h in a CO2 incubator. After washing three times with 3 ml of DMEM/BSA, 13 ,ug of h-XOD in 0.5 ml of DMEM/BSA was added and the cells were incubated at 4 'C for 2 h. At the end of the incubation period, the unbound h-XOD was removed and the cells were washed three times with 1 ml of PBS. The cells were then incubated for 10 min at 4 'C with 0.5 ml of PBS containing 10 mg/ml heparin to release h-XOD from the cell surface. After washing cells three times with 1 
RESULTS
Binding of h-XOD to heparin-Sepharose Figure 1 shows a heparin-Sepharose column chromatography of purified h-XOD. h-XOD had an affinity for heparin and eluted 
Figure 1 Heparin-Sepharose column chromatography of purffied h-XOD
The chromatography was carried out at room temperature on a heparin-Sepharose column (volume 2 ml) equilibrated with 25 mM sodium phosphate buffer, pH 7.5. A 100 ,ul portion of 200 ,ug/ml purified h-XOD was dialysed against above buffer before application to the column. The sample was applied at 1 ml/min and was eluted by a linear gradient of NaCI in the buffer [NaCI] (M)
Figure 3 Effect of TNBS and phenylglyoxal modification on h-XOD
Purified h-XOD (650 ,ug/ml) was dialysed against distilled water before use. h-XOD (100 #1rl) was incubated with 10 mM TNBS or 10 mM phenylglyoxal in 0.2 M NaHCO3 (20 ,ul) for 2 h at room temperature, followed by application on Sephadex G-25 equilibrated with 25 mM sodium phosphate buffer, pH 7.5. h-XOD fraction was pooled and concentrated with the above buffer saturated with (NH4)2SO4. Modified h-XOD sample (480 acl) re-dialysed against 25 mM sodium phosphate buffer, pH 7.5, was mixed with 120 ,ul of heparin-Sepharose gel equilibrated with the above buffer. The chromatography and the assay of h-XOD concentration were done as described in the legend to Figure 2 .
as a single peak having both catalytic and immunological activities with the buffer containing 0.3-0.4 M NaCl. The effect of pH was assessed by determining the releasing effect of stepwise addition of NaCl to h-XOD previously bound to heparin-Sepharose in the different buffers. The heparin affinity of h-XOD did not vary with pH over the range 7.5-8.5. The binding strength tended to increase at lower pH, whereas a significant decrease in heparin affinity was observed at pH 9.5 ( Figure 2 ).
Effect of protamine and heparin on binding of h-XOD to heparin-Sepharose
Protamine is one of several basic proteins that are made up of many basic amino acids and bind avidly to heparin; it is used clinically as a heparin antidote. Protamine inhibited the binding of h-XOD to heparin-Sepharose (results not shown). This binding was inhibited also by the addition of heparin (results not shown).
Modfflcation of lysine and arginine residues of h-XOD
The putative involvement of lysine and arginine residues in the binding of h-XOD to heparin-Sepharose were tested by exposing the h-XOD to the lysine-specific reagent TNBS and the argininespecific reagent phenylglyoxal. The enzymic activity of h-XOD was much inhibited by TNBS (remaining activity was 4.5 %), but not by phenylglyoxal (remaining activity was 92.0 %). After modification with TNBS there were almost no heparin-affinity forms of the h-XOD left. On the other hand, only roughly half of the h-XOD lost its affinity for heparin-Sepharose (cf. Figure  2 , pH 7.5) when arginine residues were modified with phenylglyoxal ( Figure 3) .
Binding of h-XOD to PAE cells
The binding of h-XOD to PAE cells was studied by incubating cells with h-XOD at 4°C for 2 h. The cell surface-bound h-XOD was released by the addition of heparin.
To investigate whether h-XOD bound to cells via surface heparan sulphate proteoglycans, the effect of heparin addition was examined. h-XOD was incubated in media containing 1 mg/ml heparin. The percentage of the cell-surface h-XOD was markedly reduced compared with the control test (Figure 4 ). To examine whether the removal of heparan sulphate proteoglycans on the endothelial-cell surface affected the binding of h-XOD, the cells were incubated in the presence of heparinase and/or heparitinase for 2 h at 37°C, then h-XOD was allowed to bind to the cells at 4 'C. Heparinase treatment decreased the binding of h-XOD to the cells by 68 % compared with control, and heparitinase treatment more efficiently decreased the binding by 84 % (Figure 4 ).
Heparin-induced release of h-XOD to human blood plasma Figure 5 shows that an intravenous injection of 50 i.u. of heparin/kg body weight leads to rapid 2.6-2.9-fold rise in plasma h-XOD levels. The plasma h-XOD level then slowly declined, approaching the initial values after 2 h. DISCUSSION Active oxygen species have been implicated in a number of disparate disease processes. Two possible sources have been identified for the production of active oxygen species: the enzyme XOD [14] and activated neutrophils [15] . Circulating neutrophils have long been known to be an important source of superoxide generation. On the other hand it has been proposed that the superoxide generated by XOD within the endothelial cell causes a free-radical-mediated chain reaction, and the neutrophils may then respond to the initial endothelial-cell injury and/or to the chemotactic properties of the superoxide generated by XOD [5] .
Immunohistochemical studies appear to localize XOD in the microvascular endothelium of a number of organs [1, 8] . They also showed that XOD was observed through the whole cytoplasm within the endothelial cells [8] . A model has been proposed that superoxide generated by XOD in endothelial cells may attract and activate neutrophils, which themselves actually cause most of the oxidant damage [5] . How this superoxide production by XOD within endothelial cells is communicated to the -ueutrophils is not yet entirely clear, because superoxide, being a charged molecule generated within the cell, cannot so easily diffuse through the cell membrane [16] . Recently, Bulkley [9] reported that XOD localized not only in the cytoplasm, but also on the outside surface of the endothelial-cell membrane. This would suggest that superoxide generated by XOD on the plasma membrane acts directly as a chemotactic factor, leading to accumulation, adherence and activation of neutrophils. Moreover, plasma-membrane-produced superoxide may play a role as an inactivator of nitric oxide, which is a major form of endothelium-derived relaxing factor (EDRF) [17] and second messenger to increase intracellular free-calcium concentration [18] . However, it is not clear how XOD localizes on the outside surface of endothelial-cell membrane.
The present data show the possibility that XOD localizes on the outside surface of endothelial cells by association with extracellular glycosaminoglycans. Purified h-XOD had moderate affinity for heparin-Sepharose. The binding is apparently of an electrostatic nature, because h-XOD could be displaced by a buffer containing about 0.3 M NaCl. The affinity of h-XOD for heparin might be weaker than that of antithrombin III [19] and extracellular superoxide dismutase C (EC-SOD C) [20] . Since h-XOD bears negative or no net charge at neutral pH (the pl of h-XOD is heterogeneous, ranging from 3.7 to 8.2 [10] ), negatively charged sulphate groups of heparin presumably might interact with some clusters of positively charged amino acid residues of this enzyme. At pH 9.5 the affinity of the enzyme for heparin decreased, probably owing to a weak protonation of essential basic amino acid residues. Similar effects of pH on the binding of lipoprotein lipase [21] and EC-SOD C [22] to heparinsubstituted gel had been reported. Protamine is a strongly positively charged protein and competed with h-XOD for heparin-Sepharose. These results would suggest the putative involvement of basic amino acid residues in the binding. The studies with the amino-acid specific reagents indicated that both lysine and arginine residues were involved in the binding of heparin. h-XOD comprises 7.8 % lysine and 3.4 % arginine (of the total amino acid composition) [10] . The heparin-binding sites of EC-SOD C [23, 24] and antithrombin III [25] [26] reported that an intravenous injection of 200 i.u. of heparin/ kg body weight led to a rapid 4-6-fold rise in plasma EC-SOD C. It was shown that the release of EC-SOD was heparin-dosedependent, and the percentage of an EC-SOD-releasing-activity of 50 i.u. of heparin per kg body weight was nearly 40% compared with a 200 i.u./kg injection. The ratio of the increase achieved for h-XOD seems to be roughly equal to that for EC-SOD C. The risen plasma h-XOD level slowly declined after a rapid rise, approaching the initial value after 2 h.
None of the results reported here are inconsistent with the notion that XOD localizes on the outside surface of endothelial cells by association with heparan sulphate. XOD-derived superoxide can damage both the source cell and cells in close apposition to endothelial cells, for example, adhered neutrophils. Superoxide generated extracellularly by XOD would initiate a toxic reaction at the membrane. The unsaturated fatty acids present in membrane and transmembrane proteins are susceptible to oxidative damage; increased membrane permeability can be caused by lipid peroxidation, and oxidation of structurally important proteins can cause a breakdown of plasma membrane. One might speculate that cytosolic XOD is released through the damaged plasma membrane. On the other hand, extracellularly generated superoxide may also attract and damage the neutrophils. These neutrophils would bring about the injury of tissues by release of additional active oxygen species, oxidative enzymes such as myeloperoxidase and hydrolytic enzymes.
